Organization
Boris Juelg, MD PhD
1 clinical trial
Clinical trial
A Safety, Immunogenicity and Efficacy Phase 1/2a Study of a Heterologous Ad26.Mos4.HIV, MVA-BN-HIV Vaccine Regimen Plus Broadly Neutralizing Antibodies PGT121, PGDM1400, and VRC07-523LS in HIV-1-Infected Adults on Suppressive ARTStatus: Recruiting, Estimated PCD: 2026-03-31